During the last week, we confirmed that China will shorten its IND approval time by more than one half, reducing the target for approval to four months from a range of eight to twelve months. Also confirmed was that the US FDA will start accepting all-China data as a basis for approval of drugs (see story). The news will have the effect of increasing the allure of conducting clinical trials in China.
